Affimed (NASDAQ:AFMD) Price Target Cut to $15.00 by Analysts at Wells Fargo & Company

Affimed (NASDAQ:AFMD) had its price objective reduced by Wells Fargo & Company from $20.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

AFMD has been the subject of several other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Stifel Nicolaus cut their price target on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Affimed Stock Down 1.4 %

Shares of NASDAQ AFMD opened at $2.15 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The stock has a 50 day moving average price of $3.08 and a 200 day moving average price of $4.17. Affimed has a 52 week low of $2.02 and a 52 week high of $8.95.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its stake in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the last quarter. Choreo LLC bought a new position in Affimed in the 2nd quarter valued at about $54,000. Intellectus Partners LLC raised its holdings in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares during the period. Jane Street Group LLC acquired a new stake in Affimed during the third quarter worth approximately $44,000. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.